V

Vir Biotechnology, Inc. Tech Stack

Immune-focused biotech pipeline in infectious disease and oncology

Biotechnology Research San Francisco, California 201–500 employees Founded 2016 Public Company

Vir Biotechnology is a public biotech company built on two core technology platforms—a next-generation antibody engine and a protease-releasable masking platform—to develop therapeutics in chronic hepatitis delta and oncology. The project and hiring mix reveals a company in late-stage clinical and commercial transition: active work spans formulation development, manufacturing process transfer, medical affairs readiness, and early-phase oncology trial execution, while leadership-heavy hiring (11 of 14 open roles at director/VP/senior level) signals scaling of operations, finance, and healthcare functions alongside manufacturing and logistics infrastructure.

Tech Stack 16 technologies

Core StackPython NetSuite Palo Alto Networks Cisco VMware Linux Intune PowerShell UKG Coupa Cisco Meraki Windows macOS Microsoft 365 Automox Excel

What Vir Biotechnology, Inc. Is Building

◆Challenges

Reliability and security of enterprise systems
Vulnerability management and incident response
Process optimization for biologics
Technical transfer to contract manufacturing
Hdv commercialization readiness
Launch readiness
Budget management
Managing complex early phase oncology trials
Vendor selection and management
Study timeline and budget monitoring

▲Active Projects

Third-party logistics network establishment
Vulnerability management and incident response
Liquid and lyophilized formulation development
Technical transfer of manufacturing processes
Out-licensing initiatives
Global search and evaluation
Configuration hardening assessments
Medical affairs launch readiness
Publication strategy
Large complex early phase oncology study

Hiring Activity

Steady15 roles · 6 in 30d

Department

Ops

3

Finance

2

Healthcare

2

Engineering

1

HR

1

Logistics

1

Manufacturing

1

Operations

1

Seniority

Senior

7

Director

4

VP

2

Manager

1

Company intelligence

Find more companies like Vir Biotechnology, Inc. by tech stack, pain points and active projects

Get started free

About Vir Biotechnology, Inc.

Vir Biotechnology discovers and develops medicines targeting serious infectious diseases and cancer by mobilizing immune-system mechanisms. Founded in 2016 and now public, the company operates from San Francisco with 201–500 employees. The pipeline centers on chronic hepatitis delta as the foundational program, complemented by oncology initiatives. Operations span clinical development (managing complex early-phase oncology studies), formulation and manufacturing (liquid and lyophilized work, technical transfer to contract manufacturers), and commercial launch readiness (medical affairs, publication strategy, out-licensing). The tech footprint is operationally focused: enterprise systems (Microsoft 365, Intune, Palo Alto Networks, Cisco), ERP and procurement (NetSuite, Coupa), and workforce management (UKG).

HeadquartersSan Francisco, California

Company Size201–500 employees

Founded2016

Hiring MarketsUnited States

Frequently Asked Questions

What is Vir Biotechnology's pipeline focused on?

Vir develops medicines in two main areas: chronic hepatitis delta (foundational program) and oncology. The pipeline is built on a next-generation antibody platform and a protease-releasable masking platform designed to advance candidates from concept to clinical stage.

What tech stack does Vir Biotechnology use?

Core platforms include Microsoft 365, Intune, and NetSuite for operations and finance; Coupa for procurement; UKG for workforce management; Palo Alto Networks and Cisco for security and infrastructure; and Python and PowerShell for engineering.